FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 - FFCD 0802)

Digestive and Liver Disease

Volumn 47, Issue 4, 2015, Pages 271-272

  Aparicio, Thomas ^a   Linot, Benjamin ^b   Le Malicot, Karine ^c   Bouché, Olivier ^d   Boige, Valérie ^e   François, Eric ^f   Ghiringhelli, Francois ^g   Legoux, Jean Louis ^h   Abdelghani, Meher Ben ⁱ   Phelip, Jean Marc ^j   Faroux, Roger ^h   Dahan, Laetitia ^k   Taieb, Julien ^l   Bedenne, Laurent ^m  

^a AVICENNE HOSPITAL   (France)

^b Institut de Cancérologie de l'Ouest Nantes Angers ^*  (France)

^c INSERM   (France)

^d REIMS UNIVERSITY HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g CENTRE GEORGES FRANÇOIS LECLERC   (France)

^h CH Orléans ^*  (France)

ⁱ CENTRE PAUL STRAUSS   (France)

^j SERVICE DE NEUROLOGIE   (France)

^k AIX MARSEILLE UNIVERSITY   (France)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^m HÔPITAL DU BOCAGE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FOLINIC ACID;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; DRUG SAFETY; EDITORIAL; HUMAN; INDUCTION CHEMOTHERAPY; METASTATIC COLORECTAL CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; INDUCTION CHEMOTHERAPY; LEUCOVORIN; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925343135     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.01.146     Document Type: Editorial

References (8)

1. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
2. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004, 350:2335-2342.
3. Van Cutsem E., Kohne C.H., Lang I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011, 29:2011-2019.
4. Ducreux M., Malka D., Mendiboure J., et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncology 2011, 12:1032-1044.
5. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370:135-142.
6. Seymour M.T., Maughan T.S., Ledermann J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370:143-152.
7. Chibaudel B., Maindrault-Goebel F., Lledo G., et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. Journal of Clinical Oncology 2009, 27:5727-5733.
8. Labianca R., Sobrero A., Isa L., et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Annals of Oncology 2011, 22:1236-1242.